NT 101
Alternative Names: NT-101Latest Information Update: 25 Jul 2024
At a glance
- Originator NexThera
- Class Eye disorder therapies; Peptides
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 19 Jul 2024 Preclinical trials in Wet age-related macular degeneration in South Korea (Ophthalmic) before July 2024 (NexThera pipeline, July 2024)
- 16 Jul 2024 NexThera submits a phase I/IIa Investigational New Drug (IND) application to the US FDA for Wet age-related macular degeneration
- 16 Jul 2024 NexThera plans a phase I trial for Wet age related macular degeneration in USA (Ophthalmic, drops) (NexThera website, July 2024)